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BY-NC-ND license (http://creativecomAbstract Background/Purpose: Transplant recipients are vulnerable to life-threatening com-
munity-acquired respiratory viruses (CA-RVs) infection (CA-RVI). Even if non-transplant criti-
cally ill patients in intensive care unit (ICU) have serious CA-RVI, comparison between these
groups remains unclear. We aimed to evaluate clinical characteristics and mortality of CA-
RVI except seasonal influenza A/B in transplant recipients and non-transplant critically ill pa-
tients in ICU.
Methods: We collected 37,777 CA-RVs multiplex real-time reverse transcription-polymerase
chain reaction test results of individuals aged 18 years from November 2012 to November
2017. The CA-RVs tests included adenovirus, coronavirus 229E/NL63/OC43, human bocavirus, hu-
man metapneumovirus, parainfluenza virus 1/2/3, rhinovirus, and respiratory syncytial virus A/B.
Results: We found 286 CA-RVI cases, including 85 solid organ transplantation recipients (G1), 61
hematopoietic stem cell transplantation recipients (G2), and 140 non-transplant critically illof Internal Medicine, Yonsei University College of Medicine, 211 Eonju-ro, Gangnam-gu, Seoul, 06273,
82.
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transplant recipients and non-trans
10.1016/j.jmii.2019.05.007patients in ICU (G3), excluding those with repeated isolation within 30 days. Adenovirus positive
rate and infection cases were most prominent in G2 (p < 0.001). The median time interval be-
tween transplantation and CA-RVI was 30 and 20 months in G1 and G2, respectively. All-cause in-
hospital mortality was significantly higher in G3 than in G1 or G2 (51.4% vs. 28.2% or 39.3%,
p Z 0.002, respectively). The mechanical ventilation (MV) was the independent risk factor asso-
ciated with all-cause in-hospital mortality in all three groups (hazard ratio, 3.37, 95% confidence
interval, 2.04e5.56, p < 0.001).
Conclusions: This study highlights the importance of CA-RVs diagnosis in transplant recipients
even in long-term posttransplant period, and in non-transplant critically ill patients in ICU
with MV.
Copyright ª 2019, Taiwan Society of Microbiology. Published by Elsevier Taiwan LLC. This is an
open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-
nc-nd/4.0/).Introduction
The use of effective immunosuppressant (IS) is explored to
prevent graft rejection and graft-versus-host disease
(GVHD) after solid organ transplantation (SOT) and he-
matopoietic stem cell transplantation (HSCT). However,
immunocompromised conditions induced by IS exacerbate
the risk of opportunistic infections.13 Community-
acquired respiratory viruses (CA-RVs), as well as
multidrug-resistant bacteria and molds, have increasingly
become of great importance, comprising a large burden on
posttransplant infection.24 CA-RVs can cause lower respi-
ratory tract infection (LRTI), resulting in mortality and life-
threatening morbidities in transplant recipients.58 SOT
and HSCT recipients face different hurdles, such as sus-
ceptibility to CA-RV infection (CA-RVI) within posttrans-
plant timeframe.14,9 HSCT recipients are mainly
susceptible to severe CA-RVI in the early posttransplant
period, including pre-engraftment with prolonged neu-
tropenia. SOT recipients could be at risk of CA-RVI from the
community at any time during the posttransplant
period.1,2,10
Non-transplant critically ill patients in the intensive care
unit (ICU) are another group vulnerable to invasive CA-
RVI.1115 Among patients with severe rhinovirus pneumonia
diagnosed using reverse-transcription polymerase chain
reaction (RT-PCR), transplantation did not comprise the
majority of underlying conditions (To et al., 78%; Choi
et al., 95.4%).14,15 Most patients with acute respiratory
failure by respiratory syncytial virus (RSV) were also not
transplant recipients.16
Respiratory infections caused by CA-RVs apart from
seasonal influenza A/B may have been under-diagnosed
before the introduction of multiplex RT-PCR methods.17,18
As the diagnosis of the precise species of CA-RVI became
possible, CA-RVs have had great clinical significance in
severely immunocompromised patients.19 The epidemi-
ology and clinical outcome of adenovirus (AdV), human
metapneumovirus (hMPV), parainfluenza (PIV), and RSV in
SOT and HSCT recipients have been reported during the
past few decades.4,19 However, there are few reports of
unique features and impact on outcome or mortality of CA-
RVI in non-transplant critically ill patients in ICU compared
to transplant recipients, even though many reports havel., Characteristics of community-
plant critically ill patients, Journfocused on the comparison of specific CA-RVI, particularly
seasonal influenza virus, between SOT and HSCT
recipients.19
The clinical information of CA-RVI between these sus-
ceptible groups will be helpful to clinicians if they need to
consider the different strategies or practices for treating
CA-RV, especially in severe LRTI cases, among transplant
recipients or non-transplant critically ill patients in ICU.
This study aimed to evaluate the characteristics and
outcome of symptomatic respiratory infection resulting
from CA-RVs besides seasonal influenza A/B, between non-
transplant critically ill patients admitted to the ICU and
transplant recipients.Methods
Study population and data collection
This was a retrospective cohort study. We retrieved all
data regarding 41,489 tests including multiplex RT-PCR
and culture for 12 CA-RVs of AdV, coronavirus (CoV) 229E/
OC43/NL63, human bocavirus (hBoV), hMPV, PIV 1/2/3,
rhinovirus, and RSV A/B, from SOT or HSCT recipients or
from non-transplant critically ill patients in ICU who were
18 years of age and were admitted between November
2012 and November 2017 at the Severance Hospital, a
university-affiliated tertiary-care center in Seoul. We did
not include seasonal influenza A/B, which could have been
diagnosed using rapid antigen test beside RT-PCR or cul-
ture in this study. The CA-RVs tests were performed for
patients with a suspicion of symptomatic CA-RVI based on
the respective clinician’s judgement. We excluded 3426
CA-RVs tests that were performed during the pretrans-
plant period or in recipients who received both SOT and
HSCT or re-transplantation. Thereafter, 10,616 and 3794
CA-RVs test results from SOT and HSCT recipients,
respectively, were finally included. The non-transplant
critically ill patients in ICU had undergone 23,367 CA-RVs
tests (Fig. 1). Repeated identical CA-RV isolation in one
patient within 30 days were considered as the same
infection. Therefore, the cohort included 85 (29.7%) and
61 (21.3%) CA-RVI cases in SOT and HSCT recipients,
respectively, and 140 (49.0%) CA-RVI cases in non-acquired respiratory viruses infections except seasonal influenza in
al of Microbiology, Immunology and Infection, https://doi.org/
Figure 1. Flow chart of data or case selection for community-acquired respiratory viruses infection except seasonal influenza A/
B, aThe CA-RVs tests included the multiplex RT-PCR or culture, but not antigen or serology tests. bThe 12 CA-RVs includes
adenovirus, coronavirus 229E/NL63/OC43, human bocavirus, human metapneumovirus, parainfluenza virus 1/2/3, rhinovirus and
respiratory syncytial virus A/B. cSOT, HSCT recipients and non-transplant critically ill patients in ICU. dAll recipients had received
SOT after HSCT (1 liver and 10 lung transplantations). eIn 286 tests, 5 (1.7%) positive results were 1 of coronavirus OC43, 3 of
parainfluenza virus and 1 of rhinovirus. fThe repeated identical CA-RV isolation in one patient within 30 days were considered as
same infection case. All RV cultures were negative, and positive results of CA-RVs were confirmed by multiplex RT-PCR. Abbre-
viations: CA-RV, community-acquired respiratory virus; CA-RVI, community-acquired respiratory virus infection; HSCT, hemato-
poietic stem cell transplantation; ICU, intensive care unit; RT-PCR, reverse transcription-polymerase chain reaction; SOT, solid
organ transplantation.
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This study was approved by Gangnam Severance Hospital
Institutional Review Board, and the need for informed
consent was waived due to the retrospective nature of the
study.Table 1 Frequency of community-acquired respiratory virus inf
cipients, HSCT recipients and non-transplant critically ill patients
CA-RVs Total (n Z 286) Transplant recip
SOT (n Z 85) HS
Adenovirus 40 (14.0) 10 (11.8)* 14
Bocavirus 5 (1.7) 2 (2.4) 3 (
Coronavirus 47 (16.4) 16 (18.8) 6 (
229E 11 (3.8) 6 (7.1) 1 (
NL63 12 (4.2) 4 (4.7) 3 (
OC43 24 (8.4) 6 (7.1) 2 (
hMPV 26 (9.1) 4 (4.7) 4 (
PIV 50 (17.5) 13 (15.3) 11
PIV1 10 (3.5) 3 (3.5) 1 (
PIV2 3 (1.0) 0 (0) 1 (
PIV3 37 (12.9) 10 (11.8) 9 (
Rhinovirus 85 (29.7) 32 (37.6)* 12
RSV 33 (11.5) 8 (9.4) 11
RSV A 9 (3.1) 4 (4.7) 2 (
RSV B 24 (8.4) 4 (4.7) 9 (
Data are expressed as number (percentage). All cases of community-
RT-PCR. *yIndicate statistically significant difference between two gro
hoc tests based on adjusted standardized residuals to control for t
community-acquired respiratory virus; HSCT, hematopoietic stem cel
care unit; PIV, parainfluenza virus; RSV, respiratory syncytial virus; RT
organ transplantation.
Please cite this article as: Lee KH et al., Characteristics of community-a
transplant recipients and non-transplant critically ill patients, Journ
10.1016/j.jmii.2019.05.007Detection methods of respiratory viruses
The AdvanSure RV multiplex real-time RT-PCR kit with
Taqman probe (AdvanSure; LG Life Sciences, Seoul, Southection cases except seasonal influenza A/B between SOT re-
in ICU.
ients Non-transplant critically ill
patients in ICU (n Z 140)
p-value
CT (n Z 61)
(23.0)*y 16 (11.4)y 0.039
4.9)* 0 (0)* 0.027
9.8) 25 (17.9) 0.299
1.6) 4 (2.9) 0.219
4.9) 5 (3.6) 0.797
3.3) 16 (11.4) 0.145
6.6) 18 (12.9) 0.090
(18.0) 26 (18.6) 0.842
1.6) 6 (4.3) 0.775
1.6) 2 (1.4) 0.597
14.8) 18 (12.9) 0.848
(19.7)* 41 (29.3) 0.042
(18.0) 14 (10.0) 0.214
3.3) 3 (2.1) 0.552
14.8) 11 (7.9) 0.089
acquired respiratory virus infection were diagnosed by multiplex
ups using Bonferroni corrected chi-square or Fisher’s exact post-
ype I error inflation (adjusted p < 0.05). Abbreviations: CA-RV,
l transplantation; hMPV, human metapneumovirus; ICU, intensive
-PCR, reverse transcription-polymerase chain reaction; SOT, solid
cquired respiratory viruses infections except seasonal influenza in
al of Microbiology, Immunology and Infection, https://doi.org/
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OC43/NL63, hBoV, hMPV, PIV 1/2/3, rhinovirus, and RSV A/
B from nasopharyngeal aspirate or swab, sputum, bron-
choalveolar lavage, and bronchial washing.2022 Reverse
transcription and amplification steps were automatically
conducted on the SLAN-48P/96P systems (Sansure Biotech
Inc., Changsha, Hunan Province, PRC, China). The CA-RVs
culture was performed through modified shell vial
culture.22
Definition
The CA-RVs tests have been performed when respiratory
infection symptoms such as fever, cough, and sputum
were noted, or when the patient was clinically suspected
of having a CA-RVI. In some cases, one CA-RV was
repeatedly detected at different time points and  two
CA-RVs were simultaneously detected in one patient. We
considered several isolations caused by the same CA-RV
within 30 days in one patient as one CA-RVI case.
Abnormal findings on chest radiography and/or chest
computed tomography (CT) scan was defined as the
presence of newly developed lung parenchymal infiltra-
tion, as determined by the radiologist. We categorized
seasonal variation based on spring (MarcheMay), summer
(JuneeAugust), autumn (SeptembereNovember), and
winter (DecembereFebruary).
Statistical analysis
Data were expressed as number (percent) or
mean  standard deviation or median (interquartile range
[IQR]) according to whether they followed the normal
distribution or not. Categorical variables were compared
using Chi-square test or Fisher’s exact test, and post-hoc
analysis via Bonferroni correction based on adjusted
standardized residuals was used to control for type I error
inflation (adjusted p). We used the parametric indepen-
dent T-test or analysis of variance (ANOVA) test to
compare the continuous variables with normal distribution
between two or three groups, respectively. Continuous
variables without normal distribution between two or
three groups were compared using non-parametric
ManneWhitney U test or KruskaleWallis test, respec-
tively. The post-hoc tests for continuous variables were
performed using Bonferroni correction as a parametric
test or Mann-Whitney U test as a non-parametric test
(p < 0.05/3 [0.0167]). The Kaplan-Meier survival analyses
with log-rank test were used to compare all-causes in-
hospital mortality. We performed the Cox proportional
hazard regression analysis with variables showing statis-
tical significance in univariate analyses to reveal the in-
dependent factors in relation to all-causes in-hospital
mortality. All two-tailed p-values or adjusted p-values of
0.05 except post-hoc test using Mann-Whitney U test
were considered statistically significant. All statistical
analyses and images were performed using SPSS V23
software (IBM Corp., Armonk, NY, USA) and GraphPad
Prism V6 (version 6; GraphPad Software, Inc. La Jolla, CA,
USA).Please cite this article as: Lee KH et al., Characteristics of community-
transplant recipients and non-transplant critically ill patients, Journ
10.1016/j.jmii.2019.05.007Results
Frequency of community-acquired respiratory
viruses in laboratory tests and infection cases
Any CA-RVs that were not isolated in culture had been tested
in a minority of patients (0.9%). We described the positive
rates of all kinds of CA-RVs in multiplex RT-PCR tests that
were performed based on clinical suspicion of symptomatic
CA-RVI in three different groups (Supplementary Table 1).
The positivity of rhinovirus was higher in both SOT and HSCT
recipients than in non-transplant critically ill patients in the
ICU (3.9% vs. 2.2%, p Z 0.044). In HSCT recipients, the
positive rate of AdV (4.2%) was the most prominent. The
positive rates of each CA-RV showed significant differences
between three groups for AdV (p < 0.001), hBoV (p < 0.001),
PIV3 (p Z 0.005), rhinovirus (p Z 0.044), and RSV A/B
(p Z 0.037). Overall CA-RVs positive rates were the highest
in HSCT recipients (0.9% of SOT recipients, 1.7% of HSCT re-
cipients and 0.6% of non-transplant critically ill patients in
ICU, p Z 0.034) (Supplementary Table 1). In the analyses of
the total 286 CA-RVI cases, AdV, hBoV, and rhinovirus had
significantly different proportions between three groups
(pZ 0.039, 0.027, and 0.042, respectively), with the highest
frequency in HSCT recipients for AdV and hBoV or in SOT
recipients for rhinovirus. The percentage of AdV infection in
HSCT recipients (23.0%) was significantly higher compared to
that in SOT recipients (11.8%) or in non-transplant critically
ill patients in ICU (11.4%). The HSCT recipients (19.7%) had
significantly lower percentages of rhinovirus infection than
SOT recipients (37.6%) (Table 1).
Characteristics and outcome of CA-RV infections in
three different groups
We analyzed the characteristics of CA-RVI in three groups,
and the impact of CA-RVI on the outcome of all-causes in-
hospital mortality (Table 2). The most common allograft in
CA-RVs-infected SOT recipients was kidney (48.3%), fol-
lowed by lung (25.3%) and liver (21.8%). In total, 62.3% and
91.8% of CA-RVs-infected HSCT recipients received trans-
plantation from allogeneic donor and stem cell source of
peripheral blood, respectively.
The age, male sex, and total duration of hospital stay at
the time of CA-RVI were significantly different among the
three groups (p < 0.001, 0.044 and 0.002, respectively). The
non-transplant critically ill patients in ICU were the oldest
(68  14 year-old) and had stayed in hospital during the
longest period, with median of 25 days (IQR, 11e45 days).
Total duration of ICU stay was not significantly different
between non-transplant critically ill patients in ICU and
transplant recipients who had ever received ICU (29.4% of
SOT and 29.5% of HSCT recipients). The time interval be-
tween transplantation and CA-RVI was significantly longer in
SOT recipients than in HSCT recipients (30 [10e107] vs. 20
[11e39] months, p Z 0.035) (Table 2 and Fig. 2). The season
of CA-RVI incidence was not different between three groups
(p Z 0.206). The SOT recipients had the significantly lowest
all-cause in-hospital mortality (28.2%) among the three
groups (p Z 0.002) (Table 2 and Fig. 3).acquired respiratory viruses infections except seasonal influenza in
al of Microbiology, Immunology and Infection, https://doi.org/
Table 2 Comparisons of clinical characteristics and outcome of community-acquired respiratory virusesa infection cases
except seasonal influenza A/B in SOT recipients, HSCT recipients and non-transplant critically ill patients in ICU.
Characteristics Transplant recipients Non-transplant critically
ill patients in ICU (n Z 140)
p-value
SOT (n Z 85) HSCT (n Z 61)
Age at CA-RVI, years 56.3  12.1 47.1  15.0 67.8  14.3 <0.001b
Sex, male 62 (72.9)*y 34 (55.7)* 81 (57.9)y 0.044













Tx and CA-RVI, months
30 (10e107) 20 (11e39) e 0.035
Season 0.206
Spring (n Z 97, 34%)
Summer (n Z 55, 19%)
Autumn (n Z 47, 16%)

















Abnormal CXR or chest CT 71 (83.5) 47 (77.0) 115 (82.1) 0.571
Rejectiond or GVHDe 20 (23.5) 19 (31.1) e 0.346
IVIG therapy 6 (7.1)* 13 (21.3)*y 12 (8.6)y 0.012
Mechanical ventilation 23 (27.1)* 15 (24.6)y 112 (80.0)*y <0.001
All-cause in-hospital death 24 (28.2)* 24 (39.3) 72 (51.4)* 0.002
a Include adenovirus, coronavirus 229E/NL63/OC43, human bocavirus, human metapneumovirus, parainfluenza virus 1/2/3, rhinovirus
and respiratory syncytial virus A/B.
b Post-hoc p-values were all significant between two groups.
c Data from transplant recipients who had ever received ICU care.
d Include all types (acute/chronic or antibody/cell-mediated) of rejection which were pathologically diagnosed in SOT recipients.
e Include acute or chronic GVHD in HSCT recipients. Abbreviations: CA-RV, community-acquired respiratory virus; CA-RVI, community-
acquired respiratory virus infection; CT, computed tomography; CXR, chest x-ray; GVHD, graft-versus-host disease; HSCT, hematopoietic
stem cell transplantation; ICU, intensive care unit; IVIG, intravenous immunoglobulin; SOT, solid organ transplantation; Tx,
transplantation.
Data are expressed as number (percentage) or mean  standard deviation or median (interquartile range). *yIndicate statistically sig-
nificant difference between two groups by post-hoc tests using Bonferroni correction in parametric test (p < 0.05) or ManneWhitney U
test in non-parametric test (p < 0.05/3 [0.0167]) for continuous variables or by chi-square or Fisher’s exact post-hoc tests based on
adjusted standardized residuals (adjusted p < 0.05) for categorical variables.
CA-RVs infection in transplant/non-transplant patients 5
+ MODELComparison of characteristics between patients
who died or not after CA-RV infections
The patients who died in hospital due to any cause of death
after CA-RVI were significantly older (62  15 vs. 58  17-
year-old, p Z 0.023) and had significantly higher percent-
ages of administration of intravenous immunoglobulin
(20.8% vs. 3.6%, p < 0.001) and mechanical ventilation (MV)
(78.3% vs. 33.7%, p < 0.001) than those who were alive
(Table 3). Each CA-RV-infected patient had similar rates for
all-cause in-hospital death (AdV, 42.5%; hBoV, 40.0%; CoV,
44.7%; hMPV, 42.3%, PIV 1/2/3, 40.0%; rhinovirus, 38.8%,
and RSV A/B, 48.5%).
Independent clinical factors associated with all-
causes in-hospital mortality in CA-RVs-infected
transplant recipients and non-transplant critically
ill patients in the ICU
In the analyses for relation of each CA-RV to all-cause in-
hospital mortality, three groups infected by any CA-RV did
not show significantly different mortality ratePlease cite this article as: Lee KH et al., Characteristics of community-a
transplant recipients and non-transplant critically ill patients, Journ
10.1016/j.jmii.2019.05.007(Supplementary Table 2). In Cox proportional hazard
regression model, MV was independent risk factor associ-
ated with higher all-cause in-hospital mortality (HR 3.37,
95% CI 2.04e5.56, p < 0.001). The transplantation was not
independently related to mortality (Table 4).Discussion
The frequency of each CA-RV except seasonal influenza A/B
among the three high-risk groups was heterogeneous
despite significant differences in overall frequency, with
overall frequency being the highest in HSCT recipients. This
study revealed that the proportion of CA-RV species,
vulnerable age, and all-cause mortalities in symptomatic
CA-RVI were different between SOT and HSCT recipients
and non-transplant critically ill patients in ICU group that
are populations typically at risk of invasive viral infections.
One of our major findings was that AdV caused significantly
higher rates of respiratory infection in adult HSCT re-
cipients, as compared to other non-immunocompetent
groups. Several studies reported the incidence of, and
mortality due to AdV infection in HSCT recipients ofcquired respiratory viruses infections except seasonal influenza in
al of Microbiology, Immunology and Infection, https://doi.org/
Figure 3. The comparison of all cause in-hospital mortality
between SOT recipients, HSCT recipients and non-transplant
critically ill patients in ICU with community-acquired respira-
tory virusesa infection except seasonal influenza A/B, *Log rank
test (Mantel-Cox). aInclude adenovirus, coronavirus 229E/
NL63/OC43, human bocavirus, human metapneumovirus, par-
ainfluenza virus 1/2/3, rhinovirus and respiratory syncytial
virus A/B. Aberrations: CA-RV, community-acquired respiratory
virus; HSCT, hematopoietic stem cell transplantation; ICU,
intensive care unit; SOT, solid organ transplantation.
Table 3 Comparison of characteristics between
community-acquired respiratory virusesa-infected patientsb
who died or not regardless of cause of death.
Characteristics All-cause in-hospital death p-value
Yes (n Z 120) No (n Z 166)
Age at CA-RVI, years 62.5  14.7 58.2  16.9 0.023
Sex, male 74 (61.7) 103 (62.0) >0.999
Species of CA-RV
Adenovirus 17 (14.2) 23 (13.9) >0.999
Bocavirus 2 (1.7) 3 (1.8) >0.999
CoV 229E/NL63/
OC43
21 (17.5) 26 (15.7) 0.747
hMPV 11 (9.2) 15 (9.0) >0.999
PIV 1/2/3 20 (16.7) 30 (18.1) 0.875
Rhinovirus 33 (27.5) 52 (31.3) 0.514
RSV A/B 16 (13.3) 17 (10.2) 0.456
IVIG therapy 25 (20.8) 6 (3.6) <0.001
Mechanical
ventilation
94 (78.3) 56 (33.7) <0.001
a Include adenovirus, bocavirus, coronavirus 229E/NL63/
OC43, human metapneumovirus, parainfluenza virus 1/2/3,
rhinovirus and respiratory syncytial virus A/B.
b Include SOT or HSCT recipients and non-transplant critically
ill patients in ICU. Abbreviations: CA-RV, community-acquired
respiratory virus; CA-RVI, community-acquired respiratory virus
infection; CT, computed tomography; CXR, chest x-ray; GVHD,
graft-versus-host disease; HSCT, hematopoietic stem cell
transplantation; ICU, intensive care unit; IVIG, intravenous
immunoglobulin; SOT, solid organ transplantation; Tx,
transplantation.
Data are expressed as number (percentage) or mean  standard
deviation or median (interquartile range).
Figure 2. Time intervals between transplantation and
community-acquired respiratory virusesa infection except
seasonal influenza A/B in SOT and HSCT recipients, aInclude
adenovirus, coronavirus 229E/NL63/OC43, human bocavirus,
human metapneumovirus, parainfluenza virus 1/2/3, rhinovirus
and respiratory syncytial virus A/B. The middle long and
upper/lower bars indicate median and upper/lower inter-
quartile values, respectively. Abbreviations: CA-RVI, commu-
nity-acquired respiratory virus infection; HSCT, hematopoietic
stem cell transplantation; SOT, solid organ transplantation; Tx,
transplantation.
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+ MODEL2.7e47% and 4.3e75%, respectively, which were typically
higher than SOT recipients, similar to our
findings.46,19,2327 These relatively wide ranges could be
due to the characteristics of the study population, including
potent conditioning chemotherapy and underlying hema-
tological malignancies, type or repetition of HSCT, era, and
occurrence of GVHD.23,27Please cite this article as: Lee KH et al., Characteristics of community-
transplant recipients and non-transplant critically ill patients, Journ
10.1016/j.jmii.2019.05.007In this study, a large proportion of CA-RVs except sea-
sonal influenza resulted in symptomatic respiratory infec-
tion at a late posttransplant period, with median of 20
months in HSCT and 30 months in SOT recipients. Like as
previous reports,1,2,4,9,10,28 our data also showed that the
posttransplant period in which CA-RVI occurred in SOT re-
cipients was significantly longer than that in HSCT re-
cipients. This finding suggests that physicians need to
suspect and diagnosis CA-RVI in transplant recipients with
respiratory symptoms regardless of posttransplant period.
Another important finding of this study was that non-
transplant critically ill patients in ICU group had high mor-
tality rates after CA-RVI rather than transplant recipients.
Our analyses for mortalities showed the MV as traditional
risk factor indicating severity of LRTI was independent risk
factors for all-causes in-hospital mortality in three immu-
nosuppressive groups with CA-RVI. The species of CA-RV
itself independently did not lead to increase mortality.
Even though SOT recipients with all kinds of CA-RVI had the
lowest mortality rate in the three high-risk groups, we did
not find the independent effect of SOT on all-cause mor-
tality in Cox proportional hazard regression model.
Our data showed that hBoV, a recently emerging CA-RV
in transplantation,29 occurred in only five transplant re-
cipients. Although it has been reported that hBoV can cause
severe disseminated infections in infants and children re-
cipients,30,31 the incidence, attributable mortality, andacquired respiratory viruses infections except seasonal influenza in
al of Microbiology, Immunology and Infection, https://doi.org/
Table 4 Factors in relation to all-cause in-hospital mor-
tality in transplant recipients and non-transplant critically
ill patients in ICU with community-acquired respiratory
virusa infection case except seasonal influenza A/B by cox
proportional hazard regression analysis.
Variables All cause in-hospital mortality
HR 95% CI p-value
Patient groups
Non-transplant critically
ill patients in ICU
1 (Ref.) 1 (Ref.) e
SOT recipients 0.87 0.52e1.45 0.587
HSCT recipients 0.61 0.35e1.04 0.169
Older age,  60-year-old 1.22 0.81e1.84 0.334
IVIG therapy 1.54 0.85e2.49 0.129
Mechanical ventilation 3.37 2.04e5.56 <0.001
a Include adenovirus, bocavirus, coronavirus 229E/NL63/
OC43, human metapneumovirus, parainfluenza virus 1/2/3,
rhinovirus and respiratory syncytial virus A/B. Abbreviations:
CA-RV, community-acquired respiratory virus; CI, confidence
interval; HR, hazard ratio; HSCT, hematopoietic stem cell
transplantation; ICU, intensive care unit; IVIG, intravenous
immunoglobulin; Ref., reference; SOT, solid organ
transplantation.
CA-RVs infection in transplant/non-transplant patients 7
+ MODELeffect of hBoV on graft in adult recipients remains un-
clear.29 A future multicenter observational study will be
helpful to verify the role of hBoV in severely immunocom-
promised patients.
Even though the CA-RV tests showed the lowest positive
rate in non-transplant critically ill patients in ICU group,
the frequencies of hMPV and RSV A/B infection associated
with detrimental outcomes and treated with specific anti-
viral agent,4,5,19,32 in this group were not different
compared to transplant recipients. Of 432 non-transplant
patients with suspected sepsis in the previous study, 12
(2.8%) had RSV A/B and 23 (5.3%) had hMPV.33 Gréve et al.
reported 7 (0.5%) with hMPV and 21 (1.5%) with RSV among
1407 non-transplant patients admitted to the ICU on MV
therapy in a prospective multicenter study in 2018.11
Recent reports support our findings and indicate that
hMPV and RSV should not be regarded as negligible patho-
gens and could be under-diagnosed in non-transplant criti-
cally ill patients, in particular on ventilated and ICU
care.1113,16,34 However, we do not have any consensus that
these CA-RVs are directly related to poor outcome and
attributable mortality in this population.11,12,34 In addition,
there is no standard guideline for prevention or treatment
of CA-RVs among transplant recipients and non-transplant
critically ill patients in ICU. Therefore, the guideline for
indication of surveillance or diagnostic tests as well as
treatment of specific CA-RVs in unique high-risk subpopu-
lation through further prospective studies needs to be
standardized to implement practices effectively.
This study has several limitations; (1) CA-RV tests were
performed based on the decisions of individual clinicians
and not according to a standard uniform protocol or united
prescription criteria. This could have resulted in over-
prescriptions leading to the lower positive rate, as well as
under-prescriptions as no suspicion of CA-RVI, (2) retro-
spective data collection precluded us from obtainingPlease cite this article as: Lee KH et al., Characteristics of community-a
transplant recipients and non-transplant critically ill patients, Journ
10.1016/j.jmii.2019.05.007precise incidence rates according to year or season.
Nevertheless, comprehensive data with nearly total 40,000
exclusively multiplex RT-PCR tests in our study can be seen
as a strength. In addition, the data demonstrated that re-
cipients of SOT or HSCT have different frequencies for CA-
RVI compared to non-transplant critically ill patients in ICU,
and these three high-risk groups with positive rates of each
CA-RV in RT-PCR tests were detected on a large scale at one
hospital. The data from one hospital might ensure the ho-
mogeneity of severity and consistency of laboratory tests in
the study population.
In conclusions, non-transplant critically ill patients in
ICU group with CA-RVI except seasonal influenza A/B had
higher all-cause mortality rate than in transplant re-
cipients. CA-RVI except influenza in transplant recipients
could occur in the late posttransplant period of several
years. Especially, AdV infection was the most prominent in
HSCT recipients. This study suggests the importance of
suspicion and diagnosis of CA-RVI in transplant recipients
even in the late posttransplant period, and non-transplant
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